Regeneron enters venture investing with $500M, poaches senior partner from ARCH

Re­gen­eron, the 35-year-old drug­mak­er still led by its co-founders, is get­ting in­to the ven­ture in­vest­ing are­na.

The New York phar­ma will com­mit $100 mil­lion per year for five years, it said Mon­day morn­ing. The drug­mak­er is the ex­clu­sive lim­it­ed part­ner for the fund, which launched this month un­der the name Re­gen­eron Ven­tures. It will in­vest in biotech star­tups, de­vices, tools and “en­abling tech­nolo­gies.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.